Targeting KRAS‐mutant pancreatic cancer through simultaneous inhibition of KRAS, MEK, and JAK2

The Kirsten rat sarcoma (KRAS) oncogene was considered “undruggable” until the development of sotorasib, a KRASG12C selective inhibitor that shows favorable effects against lung cancers. MRTX1133, a novel KRASG12D inhibitor, has shown promising results in basic research, although its effects against...

Descripció completa

Dades bibliogràfiques

Autors principals:	Satoru Miyazaki, Masato Kitazawa, Satoshi Nakamura, Makoto Koyama, Yuta Yamamoto, Nao Hondo, Masahiro Kataoka, Hirokazu Tanaka, Michiko Takeoka, Daisuke Komatsu, Yuji Soejima
Format:	Artigo
Idioma:	Inglês
Publicat:	Wiley 2025-02-01
Col·lecció:	Molecular Oncology
Matèries:	fedratinib KRAS MRTX1133 pancreatic cancer sotorasib trametinib
Accés en línia:	https://doi.org/10.1002/1878-0261.13751
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!